Enhanced Pilocarpine Formulations with Improved Stability and Shelf Life

Publication ID: 24-11857538_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Pilocarpine Formulations with Improved Stability and Shelf Life,” Published Technical Disclosure No. 24-11857538_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857538_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,538.

Summary of the Inventive Concept

This inventive concept introduces a system, method, and composition for preparing and manufacturing stable pilocarpine formulations with improved shelf life, addressing the limitations of existing formulations in terms of pH control, buffer composition, and storage conditions.

Background and Problem Solved

The original patent disclosed pilocarpine formulations with reduced buffer content, but these formulations still faced challenges in maintaining stability and shelf life. The new inventive concept addresses these limitations by introducing a modified buffer solution, pH adjustment, and optimized storage conditions, ensuring improved stability and shelf life of the pilocarpine compositions.

Detailed Description of the Inventive Concept

The new inventive concept comprises a system for preparing stable pilocarpine formulations, including a mixing unit for combining pilocarpine compound(s) with a modified buffer solution, and a processing unit for adjusting the pH of the resulting mixture to between about 3 and about 6. The modified buffer solution comprises a combination of citrate and phosphate buffers, allowing for more precise pH control. The pH-adjusting agent, such as sodium hydroxide, ensures the desired pH range. The resulting composition maintains at least about 99% of the pilocarpine compound originally present when stored under conditions comprising a temperature of about 25°C±2°C and a relative humidity of about 60%±5%.

Novelty and Inventive Step

The new inventive concept introduces a novel combination of modified buffer solution, pH adjustment, and optimized storage conditions, which provides a significant improvement over the existing pilocarpine formulations. The use of a citrate and phosphate buffer combination and the precise pH control using a pH-adjusting agent are new and non-obvious features that address the limitations of the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different buffer combinations, pH-adjusting agents, or storage conditions. Additionally, the system and method could be adapted for the preparation of other ophthalmic compositions or pharmaceuticals.

Potential Commercial Applications and Market

The enhanced pilocarpine formulations with improved stability and shelf life have significant commercial potential in the ophthalmic industry, particularly in the treatment of presbyopia and other age-related eye conditions. The target market includes pharmaceutical companies, ophthalmic manufacturers, and healthcare providers.

Field of Art

Pharmaceutical formulation and ophthalmic drug delivery, specifically focusing on pilocarpine-based compositions for treating ocular conditions like presbyopia

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation scientist with expertise in ophthalmic drug development, possessing knowledge of buffer systems, pH control, and pharmaceutical stability testing, typically holding a PhD or equivalent industrial experience in pharmaceutical chemistry

Obviousness Rationale

A person of ordinary skill would recognize that the PTD's modifications to the source patent represent predictable variations in pharmaceutical formulation techniques. The core innovations involve minor adjustments to buffer composition and pH control that would be considered routine optimization for a skilled formulation scientist. The PTD's approach of combining citrate and phosphate buffers and using sodium hydroxide for pH adjustment represents a straightforward extension of known pharmaceutical formulation principles.

Obvious Combinations & Variations

Source Patent Element
Pilocarpine hydrochloride composition with reduced buffer content
PTD Variation
Modified buffer solution using combination of citrate and phosphate buffers
Obviousness Reasoning
Selecting alternative buffer combinations is a standard design choice for pharmaceutical formulations, with predictable results in pH stabilization and drug preservation
Source Patent Element
pH maintenance between 3 and 6
PTD Variation
Narrowing pH range to 4.5±0.5 and using sodium hydroxide as pH-adjusting agent
Obviousness Reasoning
Fine-tuning pH parameters is a routine optimization technique in pharmaceutical development, representing an obvious refinement of existing formulation strategies
Source Patent Element
Storage stability at 25°C±2°C
PTD Variation
Enhanced stability measurement to 99% compound retention with added humidity control
Obviousness Reasoning
Incremental improvements in stability testing and storage conditions are predictable engineering variations within pharmaceutical formulation practices
Source Patent Element
Ophthalmic pilocarpine solution for treating presbyopia
PTD Variation
System and method for preparing enhanced pilocarpine formulations
Obviousness Reasoning
Developing systematic approaches to pharmaceutical preparation represents an obvious technological progression for a skilled formulation scientist
Source Patent Element
Pharmaceutical composition with pilocarpine compound
PTD Variation
Alternative embodiments adaptable to other ophthalmic compositions
Obviousness Reasoning
Generalizing a specific pharmaceutical technique to broader applications is a standard approach in drug development, representing an obvious technical extension
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857538, the present publication demonstrates that the claimed variations in pilocarpine formulation techniques would have been obvious to a person having ordinary skill in pharmaceutical formulation at the time of invention. The disclosed modifications represent routine optimization and predictable variations that do not rise to the level of non-obvious innovation, thereby establishing this publication as valid prior art under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,538
TitleStable pilocarpine formulations with modified buffer characteristics and related methods
Assignee(s)Somerset Therapeutics, LLC